AZD5634 is a compound designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance. 

Status

A phase 1b study of AZD5634 in adults with CF found that a single dose of inhaled AZD5634 did not have a significant impact on mucociliary clearance when compared with placebo. No further development in CF is planned at this time.

Sponsor

This program is sponsored by AstraZeneca. This program was conducted within the Therapeutics Development Network (TDN).